UK's Immunocore Q2 EPS misses estimates
UK's Immunocore Q2 EPS misses estimates
Overview
UK biotech firm's Q2 KIMMTRAK revenue rose 18% yr/yr, driven by higher US and global sales
Q2 adjusted EPS and net income missed analyst expectations; operating income beat estimates
Company nears enrollment target for Phase 3 TEBE-AM trial in advanced cutaneous melanoma
Outlook
Immunocore expects to pay about $120 mln in sales-related rebate accruals in H2 2026
Company sees three growth areas for KIMMTRAK, including further market penetration and label expansion
Topline data from Phase 3 TEBE-AM trial could come as early as end of 2026
Result Drivers
HIGHER SALES VOLUMES - Co said Q2 KIMMTRAK revenue growth was primarily due to increased sales volumes in US and international regions
MARKET PENETRATION - Co cited continued US community and global market penetration in metastatic uveal melanoma as a key growth driver
CLINICAL DATA IMPACT - Five-year overall survival data for KIMMTRAK underscored lasting impact and reinforced confidence in platform, per CEO Bahija Jallal
Company press release: ID:nGNE5fKlG6
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS | Miss | -$0.02 | $0.01 (13 Analysts) |
Q2 Net Income | Miss | -$808,000 | $1.08 mln (11 Analysts) |
Q2 Operating Income | Beat | -$3 mln | -$3.20 mln (12 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Immunocore Holdings PLC is $73.00, about 119.3% above its August 5 closing price of $33.29
Reuters Recommended Reads
Aug 5 - Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates
Aug 6 - UK's Hikma Pharmaceuticals H1 revenue, profit rise on strong branded drugs growth
Aug 5 - EyePoint Pharmaceuticals Q2 revenue drops on lower license income
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)